title: A Diabetes-specific Oral Nutritional Supplement Improves Glycaemic Control in Type 2 Diabetes Patients.
abstract: OBJECTIVE
  Reducing the intake of low molecular weight carbohydrates with artificial nutrition may lower glycaemic response in patients with diabetes. We evaluated effects of a diabetes-specific carbohydrate modified oral nutritional supplement (ONS) during 12 weeks administration in 40 elderly type 2 normal weight patients with diabetes with previous involuntary weight loss.
  
  
  METHODS
  Prospective, randomised, double-blind, controlled trial. Patients ingested 2×200 ml/day diabetes-specific or isocaloric standard ONS (control) in addition to their regular diet. Parameters of glucose and lipid metabolism, functional and nutritional status were assessed at baseline, weeks 6 and 12.
  
  
  RESULTS
  Postprandial glucose incremental area under the curve (iAUC0-240 min) was comparable between treatment groups on day 1 (467.9±268.4 vs. 505.1±206.1 mmol/l*min, n.s. - arithmetic means±standard deviation) and was significantly lower with the diabetes-specific ONS vs. controls in weeks 6 and 12 (355.2±115.8 vs. 634.9±205.9 and 364.9±153.1 vs. 743.4±202.7; both P<0.0001). Postprandial peak glucose was significantly lower with the diabetes-specific ONS vs. controls in weeks 6 and 12 (P<0.0001) and the decrease in HbA1c, (baseline to week 12) was markedly pronounced (P=0.028). There were no differences between groups in insulin, HOMA-IR, lipid parameters, nutritional and performance status. Body weight and body mass index (BMI) increased significantly over time in both groups.
  
  
  CONCLUSIONS
  Administration of a diabetes-specific ONS for 12 weeks reduced postprandial glycaemia after ingestion of the study treatment and improved long-term glycaemic control in elderly patients with type 2 diabetes and involuntary weight loss, thereby reducing their risk for diabetes-associated long-term complications.
authors.affiliation: Diabetology, Health Care Centre, Stockach, Germany.
authors.forename: P
authors.initials: P
authors.lastname: Mayr
authors.affiliation: Medical Writing, Stuttgart, Germany.
authors.forename: K S
authors.initials: KS
authors.lastname: Kuhn
authors.affiliation: d.s.h. Statistical Services, Rohrbach, Germany.
authors.forename: P
authors.initials: P
authors.lastname: Klein
authors.affiliation: Fresenius Kabi Deutschland GmbH, Bad Homburg, Germany.
authors.forename: J F
authors.initials: JF
authors.lastname: Stover
authors.affiliation: Fresenius Kabi Deutschland GmbH, Bad Homburg, Germany.
authors.forename: E A
authors.initials: EA
authors.lastname: Pestana
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D019587:Dietary Supplements; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D019518:Postprandial Period; D016896:Treatment Outcome